Literature DB >> 23686865

Bevacizumab: finding its niche in the treatment of heart failure secondary to liver vascular malformations in hereditary hemorrhagic telangiectasia.

Lawrence H Young1, Katharine J Henderson, Robert I White, Guadalupe Garcia-Tsao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23686865     DOI： 10.1002/hep.26472

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  3 in total

1.  Putting a new spin: MRI monitoring of hepatic artery and portal vein flow for response to bevacizumab in hereditary hemorrhagic telangiectasia.

Authors:  Numan Kutaiba; Paul J Gow; Janine French; Ruth P Lim
Journal:  Clin Case Rep       Date:  2014-11-17

2.  Bevacizumab as a treatment for hereditary hemorrhagic telangiectasia in children: a case report.

Authors:  Fabio E Ospina; Alex Echeverri; Iván Posso-Osorio; Lina Jaimes; Jaiber Gutierrez; Gabriel J Tobón
Journal:  Colomb Med (Cali)       Date:  2017-06-30

3.  Subaortic Membranes in Patients With Hereditary Hemorrhagic Telangiectasia and Liver Vascular Malformations.

Authors:  Agnes S Kim; Katharine J Henderson; Sumeet Pawar; Min Jung Kim; Shahnaz Punjani; Jeffrey S Pollak; John T Fahey; Guadalupe Garcia-Tsao; Lissa Sugeng; Lawrence H Young
Journal:  J Am Heart Assoc       Date:  2020-10-15       Impact factor: 5.501
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.